TOP EMINENT HEALTHCARE

Top Eminent Healthcare Group Limited
（卓著健康集團有限公司）*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6877)

INSIDE INFORMATION
POSITIVE PROFIT ALERT AND LITIGATION UPDATE

This announcement is made by Top Eminent Healthcare Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

POSITIVE PROFIT ALERT

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026, the Group is expected to record a consolidated net profit attributable to the Shareholders of approximately HK$1 million, representing a significant turnaround from loss to profit compared to the consolidated net loss attributable to the Shareholders of approximately HK$2.2 million for the corresponding period in 2025.

The expected turnaround from loss to profit is primarily attributable to the steady revenue growth in the Group's core healthcare business driven by the expansion of healthcare services and business-to-consumer initiatives, which offset the adverse impact of the litigation-related expenses (including the judgment sum paid to Banclogix System Co., Limited ("**Banclogix**") and increased legal fees) incurred by the Group during the period.

The Group maintains a solid liquidity position, providing a strong financial buffer to support the Group's ongoing operations.

LITIGATION UPDATE

Reference is made to the announcement of the Company dated 22 May 2026 in relation to the litigation involving the Company and Banclogix under High Court Action Nos. 1416 of 2019 and 452 of 2020 (the "**Proceedings**").

The Board wishes to inform the Shareholders and potential investors that the Company recently received letters from the legal representatives of Banclogix concerning the amount of legal costs claimed by Banclogix in connection with the Proceedings.

The Board wishes to emphasize that the amount of legal costs claimed has not been agreed by the Company and has not been determined by the Court. In the absence of agreement between the parties, the amount of legal costs payable by the Company will have to be determined by the Court through the formal taxation process to be commenced, and the Company will make further announcement(s) as and when appropriate in accordance with the Listing Rules.

The Group's healthcare business continues to operate in its ordinary course, and its normal operations have not been disrupted by the Proceedings.

GENERAL

The Company is still in the process of finalizing the interim results of the Group for the six months ended 30 June 2026. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to the unaudited consolidated management accounts currently available, which have not been audited or reviewed by the Company's auditors or its audit committee. The interim results announcement of the Company is expected to be published by the end of August 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Top Eminent Healthcare Group Limited
Ji Guangfei
Chairman

Hong Kong, 17 July 2026

As at the date of this announcement, the Board comprises four Executive Directors, namely Mr. Ji Guangfei (Chairman and Chief Executive Officer), Ms. Li Jiang (Deputy Chairman), Mr. Zhang Huanping and Ms. Wang Yinqing; two Non-Executive Directors, namely Mr. Yuan Feng and Mr. Chung Cheuk Fan Marco; and three Independent Non-Executive Directors, namely Mr. Zhou Jiannan (Lead INED), Ms. Hu Zhaoxia and Mr. Lyu Aiping.

* *For identification purpose only*